

## Press Release

**Matthias Link**  
Corporate Communications

**Fresenius Medical Care**  
Else-Kröner-Straße 1  
61352 Bad Homburg  
Germany  
T +49 6172 609-2872  
F +49 6172 609-2294  
matthias.link@fresenius.com  
www.freseniusmedicalcare.com

May 12, 2016

### **Fresenius Medical Care expects continued, strong growth – Annual General Meeting approves 19th consecutive dividend increase**

Fresenius Medical Care, the world's leading provider of dialysis products and services, expects significant sales and earnings growth in 2016. At the Annual General Meeting in Frankfurt today, CEO Rice Powell confirmed the full-year guidance announced in February. The company is targeting 7 to 10 percent revenue growth in constant currency, and an increase in net income of 15 to 20 percent.

Powell also confirmed Fresenius Medical Care's long-term financial goals: Revenue of \$28 billion is targeted for 2020, corresponding to an average growth rate of about 10 percent. Over the same period, an annual, high single-digit percent increase in net income is expected.

"We have every reason to look to the future with great confidence," Powell said in his speech to the shareholders. "In the past year, we have positioned ourselves to continue the unique success story of Fresenius Medical Care in the years to come. We will continue to grow our dialysis services and products business while actively shaping the development of the dialysis market. We are extending our range of related medical services in the area of Care Coordination."

A large shareholder majority of 99.96 percent approved the company's 19th consecutive dividend increase. The dividend will be raised from €0.78 to €0.80 per share.

All candidates for the new term of the Supervisory Board were elected by the shareholders with clear majorities. Joining the Board for the first time are Deborah Doyle McWhinney, former Chief Executive Officer and Chief Operating Officer of Citi Enterprise Payments (Citigroup, Inc.), and Pascale Witz, Executive Vice President, Global Diabetes & Cardiovascular at Sanofi S.A.

Shareholder majorities of 99.92%, respectively, approved the actions of the Management and Supervisory Boards in 2015.

At the Annual General Meeting, 77.77% of the subscribed capital was represented.

The next Annual General Meeting is scheduled for May 11, 2017.



Fresenius Medical Care is the world's largest provider of products and services for individuals with renal diseases of which about 2.8 million patients worldwide regularly undergo dialysis treatment. Through its network of 3,432 dialysis clinics, Fresenius Medical Care provides dialysis treatments for 294,043 patients around the globe. Fresenius Medical Care is also the leading provider of dialysis products such as dialysis machines or dialyzers. Along with the core business, the company focuses on expanding the range of related medical services in the field of Care Coordination. Fresenius Medical Care is listed on the Frankfurt Stock Exchange (FME) and on the New York Stock Exchange (FMS).

For more information visit the Company's website at [www.freseniusmedicalcare.com](http://www.freseniusmedicalcare.com).

#### Disclaimer

This release contains forward-looking statements that are subject to various risks and uncertainties. Actual results could differ materially from those described in these forward-looking statements due to certain factors, including changes in business, economic and competitive conditions, regulatory reforms, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, and the availability of financing. These and other risks and uncertainties are detailed in Fresenius Medical Care AG & Co. KGaA's reports filed with the U.S. Securities and Exchange Commission. Fresenius Medical Care AG & Co. KGaA does not undertake any responsibility to update the forward-looking statements in this release.